News

Andexanet alfa, which secured breakthrough therapy designation from the US FDA, is being developed as a potential first-in-class antidote to reverse the anticoagulation activity of Factor Xa inhibitor-treated

As part of the deal, arGEN-X has licensed the firm’s POTELLIGENT CHOK1SV Cell Line Technology for use in the development of ARGX-110, a proprietary antibody in its pipeline.

The deal will allow Sanofi Pasteur to access the global PCV market of $4bn and the use of PCVs in all countries is recommended by the World Health

Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. As part of the deal, Noven will grant Actavis a non-exclusive, royalty-bearing license to

A new distribution center in Singapore and the recent expansion of the company’s facilities in Billerica, Mass., will help PAREXEL more effectively manage clients’ global clinical trial supply

Under the deal, Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex. In return, Medigene will get an upfront payment

Basis of the new vaccine formulation and analysis service are advanced, precise and highly informative analytical techniques. The new service will be centred on XstalBio’s proprietary solid state

The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library partnership of this scale has been

The allowed patent is a formulation patent and covers the DETERx technology platform. As such, the claims cover multiple products in Collegium’s development pipeline. This is the sixth